Takasu Toshiaki
Rinsho Shinkeigaku. 2003 Nov;43(11):866-9.
The subacute myelo-optico-neuropathy (SMON) was hazard caused by clioquinol, an antiseptic, prescribed for the treatment of diarrhea and other bowel symptoms. Its overdosing and long-term taking led to the occurrence of SMON, for which physicians should be responsible. Clioquinol, originally a disinfectant powder for external use, was diverted later to a drug for internal use to sterilize the bowel where no intestinal absorption or action after absorption was expected. An annotation on the 6th Revision of the Japan Pharmacopoeia (1954) allowed irregular increase in its dosage depending on the severity of illness. An annotation on the 7th Revision (1961) ignoring the 6 papers published in the 1930's, 1940's or 1950's claimed that its metabolism was poorly known, yet neglected significant side effect and substantial absorption from the intestine. Its characterization as a superficial disinfectant helped the annotators be less interested in its absorption and its internal actions and side effects. Attention paid by clinicians to a polyneuropathy-like syndrome that complicated an uncontrollable hemorrhagic diarrhea (1958) and an encephalomyelitis or a paralysis of the lower half of the body associated with diarrhea or other bowel symptoms (1960, 1961) started the recognition of a new disease. During the dispute induced by the mass occurrence of the disease in several instances postmortem examination with neuropathologic expertise, especially of T. Tsubaki, Y. Toyokura and H. Tsukagoshi (1964), characterized SMON as a non-inflammatory new disease of the spinal cord, optic nerve and peripheral nerve with a pseudo-systemic degeneration of posterior and lateral columns and, therefore played a decisive role in establishing the truth of SMON. The discovery of the green hairy tongue (the tongue coated with green hairs) of SMON by T. Takasu, A. Igata and Y. Toyokura (January 1970) aroused researchers' interest in the green color of SMON and thereby began solving the cause of SMON. The discovery of the green urine in SMON patients by A. Igata, M. Hasebe and T. Tsuji (May 1970) especially facilitated the identification of the green substance in SMON that was achieved by M. Yoshioka and Z. Tamura (June 1970). The green color was derived from a chelate compound of clioquinol with ferric iron. The early epidemiological analysis related clioquinol taking to the occurrence of SMON well enough for the Japanese Government to take an administrative measure for the temporary suspension of selling clioquinol containing drugs and the postponing of their use (September 1970). Extensive and intensive multidisciplinary investigations conducted for the subsequent 20 months led to the conclusion by the SMON Investigation and Research Committee (Head: R. Kono) that the neurological disorders of patients who were diagnosed as SMON for the most part were caused by taking clioquinol (March 1972). Close clinical observation of patients opened a way to recognize a new disease and elucidate its cause. Expert specialized technical knowledge and skills established the firm knowledge of the new disease. The study of SMON began as a personal research and after its achievement was exposed to the public a great many investigators in different fields concerted efforts to solve problems. Both steps were indispensable for completing the study.
亚急性脊髓视神经病变(SMON)是由氯碘羟喹引起的危害,氯碘羟喹是一种用于治疗腹泻和其他肠道症状的抗菌剂。其过量服用和长期服用导致了SMON的发生,对此医生应承担责任。氯碘羟喹最初是一种外用消毒粉,后来被转用于内服药物,用于肠道消毒,预期在肠道内无吸收或吸收后无作用。《日本药局方》第6版(1954年)的一条注释允许根据病情严重程度不规则增加其剂量。第7版(1961年)的一条注释忽略了20世纪30年代、40年代或50年代发表的6篇论文,声称其代谢情况知之甚少,但却忽视了其显著的副作用和从肠道的大量吸收。将其描述为一种表面消毒剂使得注释者对其吸收、内服作用和副作用缺乏兴趣。临床医生对一种与无法控制的出血性腹泻并发的多发性神经炎样综合征(1958年)以及与腹泻或其他肠道症状相关的脑脊髓炎或身体下半部麻痹(1960年、1961年)的关注引发了对一种新疾病的认识。在该疾病多次大规模发生引发的争议中,尸检尤其是T. 椿、Y. 丰仓和H. 冢越(1964年)的神经病理学专业知识将SMON特征化为一种脊髓、视神经和周围神经的非炎症性新疾病,伴有后柱和侧柱的假性系统性变性,因此在确定SMON的真相方面起到了决定性作用。高须、伊贺田和丰仓(1970年1月)发现SMON患者的绿毛舌(舌苔呈绿色)引起了研究人员对SMON绿色的兴趣,从而开始探究SMON的病因。伊贺田、长谷部和辻(1970年5月)发现SMON患者的绿色尿液尤其有助于吉冈和田村(1970年6月)鉴定出SMON中的绿色物质。这种绿色来自氯碘羟喹与三价铁的螯合物。早期的流行病学分析将氯碘羟喹的服用与SMON的发生关联得足够紧密,以至于日本政府采取行政措施暂时停止销售含氯碘羟喹的药物并推迟其使用(1970年9月)。在随后的20个月里进行的广泛而深入的多学科调查导致SMON调查研究委员会(负责人:河野润)得出结论,大多数被诊断为SMON的患者的神经障碍是由服用氯碘羟喹引起的(1972年3月)。对患者的密切临床观察为认识一种新疾病并阐明其病因开辟了道路。专家的专业技术知识和技能确立了对这种新疾病的确切认识。对SMON的研究始于个人研究,在其成果公开后,许多不同领域的研究人员共同努力解决问题。这两个步骤对于完成这项研究都是不可或缺的。